Crossject

Supergenerics / France

New financing

Financing issue - 17/12/2021

Crossject has announced the issuance of convertible bonds.

It also grants free subscription rights to existing shareholders.

The financing of FY22 is thus secured and gives the group time to reach the market.

We will fine-tune our model and integrate this issuance.

Fact

Crossject has just announced the issuance of convertible bonds and the free granting of subscription rights to its shareholders.

Analysis

In an unsurprising move, the group announced it has issued \in 7.5m in convertible bonds (no coupon, issued at 92% of its nominal value and maturing on 31 December 2024), including \in 1.5m by Gemmes Venture, its main shareholder, and other qualified investors. The conversion price will be the minimum between \in 3.30 and 92% of a weighted average share price during a period before the conversion. The group also announced that existing shareholders (as at 31 December 2021) will be granted free subscription rights, every 20 rights enabling them to buy a share at a price of \in 3 between 12 January and 30 June 2022. This could lead to the issuance of 1.3m shares and a strengthening of shareholders' funds by \in 3.9m.

Altogether (i.e. including convertible bonds) the group could raise as much as €11.5m during FY22 (without taking into account potential licensing revenues or subsidies) which should rather easily fill its needs for the coming year.

Looking beyond FY22, the visibility is less clear since it is still too early to assess the potential cash inflows that could benefit the company during the coming year. However, we take the news as rather good since it secures FY22 and shows once again the confidence of its main shareholders.

Impact

We will adjust our numbers to take into account the convertible issuance.



Fabrice FARIGOULE

pharma@alphavalue.eu +33 (0) 1 70 61 10 50 cs.alphavalue.com

Company Page

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Buy	Upside: 284%
Target Price (6 months)	€ 10.4
Share Price	€ 2.70
Market Cap. €M	68.4
Price Momentum	NEGATIVE
Extremes 12Months	2.48 🕨 4.03
Sustainability score	3.7 /10
Credit Risk	DDD 🛪
Bloomberg	ALCJ FP Equity
Reuters	ALCJ.PA
(TT)	




Download Full Analysis

PERF	1w	1m	3m	1	12m
Crossject	5.26%	-8.16%	-17.6	5% -2	20.1%
Pharma	2.16%	1.25%	8.43	% 2	.1%
STOXX 600	-0.09%	-2.60%	2.28	% 20).3%
Last updated: 02/09/2021		12/20A	12/21E	12/22E	12/23E
Adjusted P/E (x)		-5.33	-9.80	4.29	1.92
Dividend yield (%	5)	0.00	0.00	0.00	0.00
EV/EBITDA(R) (x)	-11.3	-15.3	4.42	2.27
Adjusted EPS (€))	-0.49	-0.28	0.63	1.41
Growth in EPS (9	%)	n/a	n/a	n/a	123
Dividend (€)		0.00	0.00	0.00	0.00
Sales (€M)		5.73	5.86	51.9	94.6
EBIT margin (%)		0.00	0.00	100.0	100.0
Attributable net p	orofit (€M)	-10.1	-6.61	15.9	35.5
ROE (after tax) (%)	-1,072	153	2,677	134
Gearing (%)				434	131
0			~		

Company Valuation - Company Financials



Sales by Geography



Consolidated P&L Accounts

Sales

EBITDA

Change in sales

Change in staff costs

EBITDA(R) margin

Underlying operating profit

of which related to pensions

Exceptional items & other

Operating profit (EBIT)

Net financial expense

Depreciation

Corporate tax

Equity associates



12/20A

5.73

-4.39

20.0

-6.69

-117

-3.95

-10.6

-10.6

-0.54

-0.56

1.65

€M

%

%

€M

%

€M

€M

€M

€M

€M

€M

€M

€M

12/21E 12/22E

51.9

787

16.7

27.8

53.6

-3.35

24.5

24.5

-0.70

0.00

0.00

-7.85

5.86

2.17

0.00

-5.81

-99.2

-3.35

-9.16

-9.16

-0.70

0.00

0.00

3.25

Valuation Summary

Value	Weight
€14.8	40%
€9.66	40%
€ 5.40	5%
€ 5.40	5%
€1.35	5%
€0.00	5%
€10.4	100%
	€ 14.8 € 9.66 € 5.40 € 5.40 € 1.35 € 0.00

Largest comparables

- UCB Faes Farma
- Hikma Pharmaceuti... Ipsen

NAV/SOTP Calculation

Balance Sheet		12/20A	12/21E	12/22E
Goodwill	€M	0.00	0.00	0.00
Total intangible	€M	7.54	7.20	6.87
Tangible fixed assets	€M	6.76	5.96	6.10
Financial fixed assets	€M	0.11	0.11	0.11
WCR	€M	-2.05	-3.43	47.9
Other assets	€M	8.88	8.62	8.36
Total assets (net of short term liab.)	€M	21.7	19.0	69.9
Ordinary shareholders' equity	€M	-1.13	-7.50	8.69
Quasi Equity & Preferred	€M			
Minority interests	€M			
Provisions for pensions	€M		0.00	0.00
Other provisions for risks and liabilities	€M	0.13	0.13	0.13
Total provisions for risks and liabilities	€M	0.13	0.13	0.13
Tax liabilities	€M	0.00	0.00	0.00
Other liabilities	€M	6.01	6.01	6.01
Net debt (cash)	€M	16.7	20.3	55.0
Total liab. and shareholders' equity	€M	21.7	19.0	69.9
Capital Employed				
Capital employed after depreciation	€M	12.4	9.84	61.0
Profits & Risks Ratios				
ROE (after tax)	%	-1,072	153	2,677
ROCE	%	-60.3	-65.2	28.1
Gearing (at book value)	%			434
Adj. Net debt/EBITDA(R)	х	-2.50	-3.50	1.98
Interest cover (x)	х	-19.7	-13.1	35.0
Valuation Ratios				
Reference P/E (benchmark)	х	-5.33	-9.80	4.29
Free cash flow yield	%	-18.2	-5.24	-51.1
P/Book	х	-52.1	-9.13	7.82
Dividend yield	%	0.00	0.00	0.00
EV Calculation				
Market cap	€M	58.9	68.4	68.0
. Desidele es	CM	0.40	0.40	0.40

		/-		
ROCE	%	-60.3	-65.2	28.1
Gearing (at book value)	%			434
Adj. Net debt/EBITDA(R)	х	-2.50	-3.50	1.98
Interest cover (x)	х	-19.7	-13.1	35.0
Valuation Ratios				
Reference P/E (benchmark)	x	-5.33	-9.80	4.29
Free cash flow yield	%	-18.2	-5.24	-51.1
P/Book	x	-52.1	-9.13	7.82
Dividend yield	%	0.00	0.00	0.00
EV Calculation				
Market cap	€M	58.9	68.4	68.0
Market cap + Provisions	€M €M	58.9 0.13	68.4 0.13	
•				0.13
+ Provisions	€M	0.13	0.13	0.13
+ Provisions + Unrecognised acturial losses/(gains)	€M €M	0.13	0.13	0.13 0.00 55.0
+ Provisions + Unrecognised acturial losses/(gains) + Net debt at year end	€M €M €M	0.13 0.00 16.7	0.13 0.00 20.3	0.13 0.00 55.0
 + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent 	€M €M €M	0.13 0.00 16.7	0.13 0.00 20.3	0.13 0.00 55.0
 + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value) 	€M €M €M €M €M	0.13 0.00 16.7	0.13 0.00 20.3	0.13 0.00 55.0 0.00
 + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value) + Minority interests (fair value) 	€M €M €M €M €M €M	0.13 0.00 16.7 0.00	0.13 0.00 20.3 0.00	68.0 0.13 0.00 55.0 0.00 123 4.42
 + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value) + Minority interests (fair value) = EV 	€M €M €M €M €M €M €M	0.13 0.00 16.7 0.00 75.7	0.13 0.00 20.3 0.00 88.9	0.13 0.00 55.0 0.00

Analyst : Fabrice Farigoule, Changes to Forecasts : 02/09/2021.

Equity accordiated					10101 010
Minority interests	€M				Tax liabilitie
Adjusted attributable net profit	€M	-10.1	-6.61	15.9	Other liabili
NOPAT	€M	-7.45	-6.41	17.1	Net debt (ca
Cashflow Statement					Total liab. a
EBITDA	€M	-6.69	-5.81	27.8	Capital E
Change in WCR	€M	0.96	1.39	-51.4	Capital emp
Actual div. received from equity holdi	€M	0.00	0.00	0.00	Profits &
Paid taxes	€M	1.65	3.25	-7.85	ROE (after
Exceptional items	€M	0.00	0.00	0.00	ROE
Other operating cash flows	€M	0.00	0.00	0.00	Gearing (a
Total operating cash flows	€M	-4.09	-1.17	-31.4	Adj. Net de
Capital expenditure	€M	-6.10	-1.72	-2.66	Interest co
Total investment flows	€M	-6.10	-1.72	-2.66	
Net interest expense	€M	-0.54	-0.70	-0.70	Valuation
Dividends (parent company)	€M				Reference
Dividends to minorities interests	€M	0.00	0.00	0.00	Free cash fl
New shareholders' equity	€M	0.00	0.00	0.00	P/Book
Total financial flows	€M	-1.00	13.2	24.1	Dividend yie
Change in cash position	€M	-11.2	10.3	-9.96	EV Calcu
Free cash flow (pre div.)	€M	-10.7	-3.59	-34.7	Market ca
Per Share Data					+ Provision
No. of shares net of treas. stock (year	Mio	22.4	25.3	25.2	+ Unrecogn
Number of diluted shares (average)	Mio	20.5	24.0	25.4	+ Net debt a
Benchmark EPS	€	-0.49	-0.28	0.63	+ Leases de
Restated NAV per share	€				- Financial f
Net dividend per share	€	0.00	0.00	0.00	+ Minority in
					= EV
					EV/EBITDA

© 2021, AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein in sa been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information net inselading at the time of publication, we make no representation that it is accurate or completed must be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.